Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 700-589-0 | CAS number: 1369492-52-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Acute oral or dermal effects of this mixture are derived from toxicological information about the endproduct, the main by product and one toxicological relevant impurity. Two GLP conform studies in rats according OECD guideline 423 and 402 were performed with the end product. No mortalities occured, clinical signs resolved within post observation period. Single oral application (OECD guideline 401) of the by product to rats at 1250, 1600 and 2000 mg/kg bw resulted in mortalities and severe clinical signs. Single dermal application of the by product onto rabbit skin did not induce any adverse effects. The mixture is present as a salt and has a pH of 5 which indicates that corrosive effects after oral exposure will be less pronounced in comparison to the pure by product.
Key value for chemical safety assessment
Additional information
Reasons for read across
The substance was not tested for acute oral or dermal toxicity. The test item is a mixture which consist mainly of the end product (app. 50 %) and a by product (app. 30 %) as well as of different impurities and isomers of the end product. Therefore, information about acute toxicity are derived from studies with the end product and the by product. Moreover, one toxicological relevant impurity exceeds 1 % and is also taken into account for this summary.
Performance and observations
To evaluate oral and dermal acute toxicity of the main product, acute oral and dermal toxicity studies were performed.
A GLP conform study was performed to assess the acute oral toxicity in the rat according to OECD guideline 423.
The test substance was administered by oral gavage to three Wistar rats of each sex at 2000 mg/kg body weight. Animals were subjected to daily observations and weekly determination of body weight. Macroscopic examination was performed after terminal sacrifice (day 15).
No mortality occurred. Hunched posture, uncoordinated movements and/or lethargy were shown by the females on days 1 and/or 2, while piloerection was shown by one male on day 1. Additionally, one male and one female animal showed green faeces between days 3 and 7. No abnormalities were found at macroscopic post mortem examination of the animals. The oral LD50 value of the test substance in Wistar rats was established to exceed 2000 mg/kg body weight.
A GLP conform study was performed to assess the acute dermal toxicity in the rat according to OECD guideline 402.
The test substance was administered to five Wistar rats of each sex by dermal application at 2000 mg/kg body weight for 24 hours. Animals were subjected to daily observations and weekly determination of body weight. Macroscopic examination was performed after terminal sacrifice (day 15).
No mortality occurred. Two males showed ptosis, hunched posture and/or piloerection on days 1 and/or 2. Other clinical signs noted during treatment among all animals consisted of chromodacryorrhoea, scales and/or scabs. The animals had recovered from the symptoms between days 7 and 15. No abnormalities were found at macroscopic post mortem examination of the animals. The dermal LD50 value of the test substance in Wistar rats was established to exceed 2000 mg/kg body weight.
Acute oral toxicity of the by product was evaluated in a GLP conform study according OECD guideline 401. The test substance was administered by oral gavage to five Wistar rats of each sex at 1250, 1600 and 2000 mg/kg body weight. Animals were subjected to daily observations and weekly determination of body weight. Macroscopic examination was performed after terminal sacrifice (day 28).
Two male animals died at 2000 mg/kg bw. Two, three and four female animals died at 1250, 1600 and 2000 mg/kg bw, respectively. Mortalities occurred up to day 13. Respiration, locomotion and reflexes were impaired. Ventral position, blepharoplegia, lacrimation, miosis and diarrhoea were observed. Moreover, animals showed tactile hyperaesthesia, bloody crusted snouts and eyelids and swelled abdomen. Macroscopic examination of dead animals revealed discolorations at liver, pancreas, gastrointestinal tract and connective tissue as well as gastrointestinal bleeding and ablation of gastrointestinal mucosa. Moreover, clear red-yellowish secrete was found in abdomen. Examination of sacrificed animals revealed pathological findings at spleen, lung, adrenal glands and gastrointestinal tract. Partially, the stomach was adhered to surrounding tissue. Body weight gain was decreased up to the end of the post observation period. Based upon the findings of this study, LD50 is considered to be 1410 mg/kg bw.
In another, non-GLP study, six (3 male, 3 female)white rabbits received a single dermal application of the test article at a dose level of 2000 mg/kg bw. The skin of three animals (2 male, 1female) was abraded; the remaining animal’s skin remained intact. The test sites were occluded for 24 hours, at which time the occlusive wrap and any remaining test article were removed. Animals were observed tor pharmacologic activity and drug toxicity 1, 3, 6, and 24 hours after treatment, and daily thereafter tor a total o1 14 days. Non-survivors and anima1s surviving the 14 day observation period were subjected to gross necropsy, with all findings noted.
No unscheduled mortalities occurred. Any clinical symptoms or abnormalities were not observed.
Information about acute toxicity of the impurity is not available.
Discussion
Oral application of the end product did not induce any mortalities or signs of toxicity. One male and one female animal showed green faeces between days 3 and 7. No explanation can be given for this finding. It might be related to staining properties of the test substance.
After dermal application, yellow staining of the treated skin was observed. The test item is a dye and coloration of skin is therefore not considered as an adverse effect.
Oral administration of the by product to Wistar rats leads to mortalities and severe clinical signs. Thus, this substance is considered to be as toxic if swallowed. However, dermal application did not induce any adverse effects.
Due to the acute oral toxicity of the by product which accounts for 30% of the test item, toxic effects after oral exposure to the mixture cannot be excluded. On the other hand, the mixture is present as a salt and has a pH of 5 which indicates that the corrosive effects will be less pronounced in comparison to the by product.
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.